ASHP therapeutic position statement on the recognition and treatment of depression in older adults

American Journal of Health-System Pharmacy

Volumn 55, Issue 23, 1998, Pages 2514-2518

  Semla, Todd P ^a   Watanabe, Mark D ^a  

^a NONE

Author keywords

American Society of Health System Pharmacists; Antidepressants; Costs; Depression; Diagnosis; Dosage; Drug interactions; Drugs; Education; Geriatrics; Health professions; Organizations; Pharmacists; Protocols; Public health; Toxicity

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; DRUG CHOICE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; MEDICAL SOCIETY; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEXUAL DYSFUNCTION; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 0032407176     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.23.2514     Document Type: Article

References (35)

1. Hirschfeld RMA, Keller MB, Panico S et al. The National Depressive and Manic-Depressive Association consensus Statement on the imdertreatment of depression. JAMA. 1997; 277:333-40.
2. Lebowitz BD, Pearson JL, Schneider LS et al. Diagnosis and treatment of depression in late life. Consensus statement update. JAMA. 1997; 278:1186-90.
3. Kalayam B, Shanoian CA. Treatment of depression: diagnostic considerations. In: Salzman C. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins; 1992.
4. Rovner BW, German PS, Brant LJ et al. Depression and mortality in nursing homes. JAMA. 1991; 265:993-6.
5. Reifler BV, Larson E, Hanely R. Coexistence of cognitive impairment and depression in geriatric outpatients. Am J Psychiatry. 1982; 139:623-6.
6. Dooneief G, Mirabello E, Bell K et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol. 1992; 49:305-7.
7. Davenport RJ, Dennis MS, Wellwood I et al. Complications after acute stroke. Stroke. 1996; 27:415-20.
8. Emptage RE, Semla TP. Depression in the medically ill elderly: a focus on methylphenidate. Ann Pharmacother. 1996; 30:151-7.
9. Suicide among older persons - United States, 1980-1992. MMWR. 1996; 45:3-6.
10. Statistical abstract of the United States: 1997. Washington, DC: U.S. Bureau of the Census; 1997.
11. NIH Consensus Development Panel on Depression in Late Life. Diagnosis and treatment of depression in late life. JAMA. 1992; 268:1018-24.
12. Hughes D, Morris S, McGuire A. The cost of depression in the elderly: effects of drug therapy. Drugs Aging. 1997; 10:59-68.
13. DSM-IV: Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
14. Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1983; 17:1737-49.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
16. Ganzini L, Walsh JR, Millar SB. Drug-induced depression in the aged: what can be done? Drugs Aging. 1993; 3:147-58.
17. Gerson SC, Plotkin DA, Jarvik LF. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. J Clin Psychopharmacol. 1988; 8:311-22.
18. Clinical practice guideline no. 5. Depression in primary care. Vol. 2. Treatment of major depression. Washington, DC: U.S. Department of Health and Human Services, 1993; AHCPR publication no. 93-0551.
19. Roose SP, Laghrissi-Thode F, Kennedy JS et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998; 279:287-91.
20. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc. 1990; 65:1227-36.
21. Bressler R, Katz MD. Drug therapy for geriatric depression. Drugs Aging. 1993; 3:195-219.
22. Von Moltke LL, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of antidepressants in the elderly: therapeutic implications. Clin Pharmacokinet. 1993; 24:141-60.
23. Roose SP, Glassman AH, Attia E et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994; 151:1735-9.
24. Perry PJ. Pharmacotherapy of major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord. 1996; 39:1-6.
25. Teri L, Reifler BV, Veith RC et al. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol. 1991; 46:P372-7.
26. Reifler BV, Teri L, Raskind M et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry. 1989; 146:45-9.
27. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry. 1997; 154(5, suppl):1-39.
28. Depression clinical practice guidelines. Columbia, MD: American Medical Directors Association; 1996.
29. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry. 1993; 150(4, suppl):1-26.
30. Linde K, Ramirez G, Mulrow CD et al. St. John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ. 1996; 313:253-8.
31. Chavez ML, Chavez PI. Saint John's wort. Hosp Pharm. 1997; 32:1621-32.
32. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998; 18:84-112.
33. Nelson JC, Jatlow PI, Mazure C. Desipramine plasma levels and response in elderly melancholic patients. J Clin Psychopharmacol. 1985; 5:217-20.
34. Bodkin JA, Lasser RA, Wines JD Jr et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997; 58:137-45.
35. Antidepressant discontinuation syndrome: update on SSRI's.J Clin Psychiatry. 1997; 58(suppl 7):1-40.